Overview of the progress on haploidentical hematopoietic transplantation

Table 1 Unmanipulated haploidentical hematopoietic stem cell transplant vs matched related and matched unrelated hematopoietic stem cell transplant

Ref.	Disease	Conditioning regimen (n)	Graft type (n)	GVHD prophylaxis	Neutrophil engraftment	Grade II-IV acute GVHD	Chronic GVHD	Relapse rate	DFS	OS
Bashey et al[69] 2013 n = 271	Acute leukemia/CML/myeloma/lymphoma/MDS	RIC (102) MA (169)	MRD (117) MUD (101) Haplo (53)	CNI based CNI based CNI + MMF + PT-Cy	NR	6 mo 27% 39% 30% (P = NS)	2 yr 54% 54% 38% (P < 0.05)	2 yr 34% 34% 33% (P = NS)	2 yr 53% 52% 60% (P = NS)	2 yr 76% 67% 64% (P = NS)
Di Stasi et al[70] 2014 n = 227	AML/MDS	RIC (227)	MRD (81) MUD (108) Haplo (32)	CNI + MTX CNI + MTX + ATG CNI + MMF + PT-Cy	30 d 99% 96% 97% (P = 0.44)	100 d 24% 19% 26% (P = 0.68)	3 yr 46% 42% 24% (P = 0.52)	1 yr 28% 23% 33% (P = 0.75)	3 yr 36% 27% 30% (P = 0.12)	NR
Luo et al[71] 2014 n = 305	Acute leukemia/lymphoma/MDS	MA + ATG (305)	MRD (90) MUD (116) Haplo (99)	CNI + MMF + MTX CNI + MMF + MTX CNI + MMF + MTX	15 d 97% 97% 78% (P < 0.001)	3 mo 15.60% 39% 42% (P < 0.0001)	2 yr 24% 41% 41% (P = NS)	5 yr 34% 21% 14% Haplo vs MRD P = 0.008 Haplo vs MUD P = 0.17	5 yr 63% 58% 58% (P = 0.57)	5 yr 77% 63% 60.80% Haplo vs MRD P = 0.026 Haplo vs MUD P = 0.38
Ciurea et al[63] 2015 n = 2174	AML	RIC (825) MA (1349)	MUD (737) Haplo (88) MUD (1245) Haplo (104)	CNI + MMF or MTX CNI + MMF + PT-Cy CNI + MMF or MTX CNI + MMF + PT-Cy	30 d 93% 96% (P = 0.25) 90% 96% (P = 0.02)	3 mo 19% 28% (P = 0.05) 16% 33% (P = 0.001)	3 yr 34% 52% (P = 0.002) 30% 53% (P < 0.0001)	3 yr 58% 42% (P = 0.006) 44% 39% (P = 0.37)	3 yr 9% 23% (P = 0.0001) 14% 20% (P = 0.14)	3 yr 46% 44% (P = 0.71) 45% 50% (P = 0.38)
Wang et al[64] 2015 n = 450	AML in CR1	MA (ATG in haplo cohort)	MRD (219) Haplo (231)	CNI + MMF + MTX CNI + MMF + MTX	NE engraftment 2 d longer after MRD P = 0.004	100 d 36% 13% (P < 0.001)	1 yr 42% 15% (P < 0.001)	3 yr 15% 15% (P = 0.98)	3 yr 74% 78% (P = 0.34)	3 yr 79% 82% (P = 0.36)
Ghosh et al[67] 2016 n = 987	Lymphoma	RIC (987)	MRD (807) Haplo (180)	CNI based PT-Cy ± CNI	28 d 95% 97% (P = 0.31)	100 d 25% 27% -0.84	1 yr 45% 12% (P < 0.001)	3 yr 37% 40% (P = 0.51)	3 yr 48% 48% (P = 0.98)	3 yr 62% 61% (P = 0.82)
Kanate et al[72] 2016 n = 917	Lymphoma	RIC (917)	MUD + ATG (241) MUD (491) Haplo (185)	CNI based CNI based PT-Cy based	28 d 97% 97% 94% (P = 0.32)	100 d 17% 12% 8% (P = 0.44)	1 yr 33% 51% 13% (P < 0.001)	3 yr 36% 28% 36% (P = 0.07)	3 yr 38% 49% 47% (P = 0.02)	3 yr 50% 62% 60% (P = 0.2)

AML: Acute myeloid leukemia; ATG: Anti-thymocyte globulin; CR: Complete remission; CNI: Calcineurin inhibitor; DFS: Disease free survival; GVHD: Graft vs host disease; Haplo: Haploidentical; MMF: Mycophenolate mofetil; MTX: Methotrexate; RIC: Reduced intensity conditioning; MA: Myeloablative; MDS: Myelodysplasia; MUD: Matched unrelated donor; MRD: Matched related donor; NE: Neutrophil; NR: Not reported; NS: Not significant; OS: Overall survival.